Eiko Lifesciences Ltd Financials
Company Logo

Eiko Lifesciences Ltd Financial Statement

Eiko Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue7.87
Operating Expense7.39
Net Profit0.21
Net Profit Margin2.67
Earning Per Share0.16
EBIDTA0.46
Effective Tax Rate10.42
Invest in Eiko Lifesciences Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Eiko Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual27.93
Operating Expenses Annual26.32
Operating Profit Annual1.79
Interest Annual0.14
Depreciation0.66
Net Profit Annual0.75
Tax Annual0.23

Eiko Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.61
Cash Flow from Operations-7.08
Cash Flow from Investing-0.55
Cash Flow from Financing20.36
Cash Flow at the End13.35

Eiko Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)6.44
PBIT Margin (%)4.08
PBT Margin (%)-22.88
Net PROFIT Margin (%)2.69
Return On Networth / Equity (%)1.87
Return On Networth /Employed (%)2.82
Return On Assets (%)1.88
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.70

Eiko Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual13.57
Total Current Assets Annual30.93
Non Current Assets Annual21.81
Total Shareholders Funds Annual50.68
Total Assets Annual52.74

Eiko Lifesciences Ltd Earning Calls

EPS (INR)

Expected

0.22

Reported

0.22

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Sep 2020

EPS beaten by 0.00%

Jun 2020

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 23, 2024, Eiko Lifesciences Ltd has a market capitalization of 60.18 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Eiko Lifesciences Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Eiko Lifesciences Ltd recorded a total revenue of approximately 27.93 Cr marking a significant milestone in the company's financial performance.
Eiko Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.0% annually, respectively..
Eiko Lifesciences Ltd's current PE ratio is 80.24.
Eiko Lifesciences Ltd's ROCE averaged 3.5% from the FY ending March 2022 to 2024, with a median of 4.0%. It peaked at 4.2% in March 2022, reflecting strong capital efficiency over the period..
Eiko Lifesciences Ltd's latest EBIT is Rs. 1.12 Cr, surpassing the average EBIT of Rs. 1.23 Cr over the 5 years..